Skip to main content

Severe chronic active hepatitis induced by UFTR containing tegafur and uracil

Digestive Diseases and Sciences volume 40, pages 2434–2437 (1995)Cite this article

Summary

A 77-year-old female patient developed severe hepatic injury after the administration of UFTR, which contains tegafur and uracil, for postoperative chemotherapy of colon cancer. Liver damage was recognized 10 months after its administration. Serum markers for viral hepatitis and various autoantibodies were negative. The wedged biopsied liver specimen revealed advanced chronic active hepatitis with periportal confluent necrosis, marked intralobular spotty necrosis, and significant proliferation of pseudo-bile ductules. Although the cessation of the drug and conservative therapies improved hepatic function, an accidental readministration of UFTR caused her severe hepatic damage again. These findings suggest that liver injury in the present case was caused by UFTR. Histological findings were unique. Although tegafur is known to worsen hepatic function when given to patients with liver cirrhosis, UFTR may also cause severe hepatic injury in those without preexisting liver disease.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Ikeda K, Kumada H, Arase Y, Nakamura I, Chayama K, Murashima N, Takeuchi K, Nakajima M, Yoshiba A, Irimoto M: Effects and side effects of the long-term administration of oral antitumor agents for patients with hepatocellular carcinoma—especially, relation to aggravation of liver function. Jpn J Gastroenterol 84:2377–2385, 1987 (abstract in English)

    Google Scholar 

  2. Ikeda K, Kumada H, Arase Y, Chayama K, Gunji T, Yoshiba A, Irimoto M: Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patient with hepatocellular carcinoma associated with liver cirrhosis—relationship with serum concentration of anti-tumor agents and side effect. Jpn J Gastroenterol 85:2411–2419, 1988 (abstract in English)

    Google Scholar 

  3. Arase Y, Ikeda K, Kumada H, Chayama K, Saito S, Gunji T, Murashima T, Takeuchi K, Nakajima M, Yoshibara A, and Umigami M: Clinicopathological investigation on acute and chronic hepatic failure death caused to patients with hepatocellular carcinoma by oral anticancerous drugs. Jpn J Gastroenterol 85:488, 1988 (in Japanese).

    Google Scholar 

  4. Ikeda K and Kumada H: Clincopathological prognosis of cases with acute and chronic hepatic failure caused by cytotoxic agents. Jpn J Gastroenterol 85:1899, 1988 (in Japanese).

    Google Scholar 

  5. Seki S, Mizoguchi Y, Saito S, Shiomi S, Sakagami Y, Sokaguchi H, Kuroki T, Harihara S, Kobayashi K, Monna T, Yamamoto S: A clinicopathological study of 11 patients with drug-induced acute hepatic failure. Jpn J Gastroenterol 83:2545–2549, 1986 (abstract in English)

    Google Scholar 

  6. Baba M, Shima T, Tanaka T, Nakayabu M, Hasegawa H, Suzuki S, Kusano I: A case of allergic liver injury induced by tegafur. J Gastroenterol 29:88–92, 1994

    PubMed  Google Scholar 

  7. Abe Y, Ueda K, Ashida H: A case of drug-induced liver injury by tegafur. Acta Hepatol Jpn 31 (suppl. 2):85, 1990 (in Japanese).

    Google Scholar 

  8. Willis CM, John KB: Drug-induced chronic liver disease. Gastroenterology 72:1348–1353, 1977

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. From the Department of Internal Medicine, Yokosuka Kyosai Hospital, Yokosuka-shi, 238, Kanagawa, Japan

    Fumie Kobayashi MD, Takaaki Ikeda MD, Naoya Sakamoto MD, Masayuki Kurosaki MD, Shinichi Tozuka MD, Shigemi Sakamoto MD, Toshiko Fukuma MD, Fumiaki Marumo MD &  Chifumi Sato MD

  2. Second Department of Internal Medicine, and Division of Health Science, Faculty of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113, Tokyo, Japan

    Fumie Kobayashi MD, Takaaki Ikeda MD, Naoya Sakamoto MD, Masayuki Kurosaki MD, Shinichi Tozuka MD, Shigemi Sakamoto MD, Toshiko Fukuma MD, Fumiaki Marumo MD &  Chifumi Sato MD

Authors
  1. Fumie Kobayashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaaki Ikeda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoya Sakamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayuki Kurosaki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Tozuka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shigemi Sakamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiko Fukuma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fumiaki Marumo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chifumi Sato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kobayashi, F., Ikeda, T., Sakamoto, N. et al. Severe chronic active hepatitis induced by UFTR containing tegafur and uracil. Digest Dis Sci 40, 2434–2437 (1995). https://doi.org/10.1007/BF02063250

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02063250

Key words

  • chronic active hepatitis
  • drug-induced hepatitis
  • tegafur
  • UFTR